Enzon Pharmaceuticals, Inc.

Common Stock SEC Reporting - Current
Verified Company Profile 6/20/2017
Contact Info
  • 20 Commerce Drive, Suite 135
  • Cranford, NJ 07016

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Jun 30, 2017 10-Q
CIK 0000727510
Fiscal Year End 12/31
OTC Marketplace OTCQX U.S.
Profile Data
SIC - Industry Classification 2836 - Biological products, except diagnostic
Incorporated In: DE, USA
Year of Inc. 1983
Employees Not Available
Company Officers/Contacts
Andrew Rackear CEO, Secretary
Richard L. Feinstein CFO
Company Directors
Jonathan Christodoro Chairman
Odysseas Kostas
Jennifer McNealey
Company Notes
  • Sponsored for OTCQX by Burns, Figa & Will, P.C. on 08/09/2016
  • Formerly=Enzon, Inc. until 12-02
Service Providers
OTCQX Advisor
Not Available
Accounting/Auditing Firm
EisnerAmper LLP
750 Third Avenue
New York, NY, 10017
United States

Legal Counsel
Curtis, Mallet, Prevost
101 Park Avenue
35 Floor
New York, NY, 10178
United States

Investor Relations Firm
Not Available
ENZN Security Details
Share Structure
Market Value1 $16,801,549 a/o Aug 17, 2017
Authorized Shares 170,000,000 a/o Dec 31, 2016
Outstanding Shares 44,214,603 a/o Mar 31, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 44,083,157 a/o Mar 31, 2017
Par Value 0.01
Shareholders of Record 941 a/o Mar 24, 2017
Short Selling Data
Short Interest 54,366 (1.46%)
Jul 31, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security